Table 1.
Demographics and characteristics of the completer population
| Treatment sequence |
|||||
|---|---|---|---|---|---|
| ABCED | ACDBE | ADECB | AEBDC | Overall | |
| (N = 13) | (N = 12) | (N = 10) | (N = 11) | (N = 46) | |
| Male, N (%) | 9 (69.2) | 9 (75.0) | 9 (90.0) | 9 (81.8) | 36 (78.3) |
| Female, N (%) | 4 (30.8) | 3 (25.0) | 1 (10.0) | 2 (18.2) | 10 (21.7) |
| Race, N (%) | |||||
| White | 13 (100) | 10 (83.3) | 10 (100) | 11 (100) | 44 (95.7) |
| Black | 0 | 2 (16.7) | 0 | 0 | 2 (4.3) |
| Age, y, mean (SD) | 28.9 (9.6) | 30.3 (10.7) | 27.1 (4.9) | 25.6 (5.1) | 28.1 (8.1) |
| Weight, lb, mean (SD) | 164.5 (28.4) | 161.3 (17.4) | 160.9 (21.0) | 160.0 (36.4) | 161.8 (26.0) |
| Body mass index, kg/m2, mean (SD) | 24.7 (3.0) | 24.8 (2.5) | 23.2 (2.8) | 23.1 (3.3) | 24.0 (2.9) |
A = intranasal (IN) high-volume (HV) morphine-abuse-deterrent, extended-release injection-molded (ADER-IMT) tablets (60 mg manipulated tablet); B = IN low-volume (LV) morphine-ADER-IMT (60 mg manipulated/sieved tablet); C = IN morphine ER (60 mg manipulated tablet); D = oral morphine-ADER-IMT (60 mg; intact); E = placebo.